NanoViricides' CEO Comments on Decline in Company Share Price
WEST HAVEN, Conn., Nov 08, 2006 (BUSINESS WIRE) -- Eugene Seymour MD, MPH, CEO of NanoViricides, Inc. (Pink Sheets: NNVC) stated today that the Company knows of no reason for the recent drop in the price of the Company's shares.
Dr. Seymour said, "we are meeting our development goals faster then initially anticipated. During the past year we have achieved outstanding results, both in-vivo and in-vitro, on our anti-human influenza and anti-avian influenza drugs. Nothing has changed in the fundamentals of the company that should cause such a precipitous decline in share price
The Company has an aggressive development plan for the following year that takes into account the current world-wide concern over the possibility of an avian flu pandemic. Although stories about avian flu have virtually disappeared from the media, the possibility of a pandemic remains a serious concern for governments around the world. Information about avian influenza can be found at the official US government site, www.pandemicflu.gov
Dr Seymour has been invited to address the Third International Bird Flu Summit which will be held next week in Geneva, Switzerland. His talk, entitled The Use of a New Class of Drugs for the Treatment of Bird Flu: Nanotechnology-based Targeted Anti-Viral Therapeutics will be delivered to the attendees of the conference on November 15th. Information on the conference is available at www.bfsummit.com
About NanoViricides - www.nanoviricides.com
NanoViricides, Inc. is a development stage company that is creating special purpose nanomaterials for viral therapy. A NanoViricide(TM) is a specially designed, flexible, nanomaterial that contains an encapsulated active pharmaceutical ingredient and targets it to a specific type of virus, like a guided missile. NanoViricide drugs are designed to block and dismantle the virus particles before they can infect a cell, thereby controlling viremia. This is a completely novel approach that is proving to be superior to existing approaches. This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Forward-looking statements involve risks and uncertainties. Actual events could differ materially and substantially from those projected herein and depend on a number of factors including the success of the Company's research and development strategy, the availability of adequate financing, the successful and timely completion of clinical studies and the uncertainties related to the regulatory process.
SOURCE: NanoViricides, Inc.
CONTACT: NanoViricides, Inc.
Leo Ehrlich, 917-853-6440
leo@nanoviricides.com |
